| April 21-28, 2015|
Numbers of the Year ...
||Minimum annual amount of "allowable"* NIH AIDS funding that Emory University needs to receive each year during both FY2015 and FY2016 in order to qualify for requesting an increase to "Tier II" funding at our next competitive renewal |
So how have we been doing towards that goal?
||FY12 allowable* funding total
||FY13 allowable* funding total
THIS JUST IN...
||FY14 allowable* funding total
Watch the CFAR Leadership react to the news
*NIH includes only specified mechanisms and grants in the "allowable" total
... to the 51 PIs whose 75 awards appearing on the FY14 NIH CFAR "Allow" Tab, totaled $50,277,124 in funding for Fiscal Year 2014; the highest in CFAR's history:
Susan Allen, Rama Amara, Albert Anderson, Deborah Anderson, Aftab Ansari, Hank Blumberg, Jeremy Boss, Siddappa Byrareddy, Hannah Cooper, Cheryl Day, Cindy Derdeyn, Ralph Diclemente, Allison Eckard, Brian Evavold, Neel Gandhi, Neela Goswami, Arash Grakoui, David Guidot, Lisa Haddad, Marcia Holstad, Eric Hunter, Ameeta Kalokhe, Colleen Kelley, Baek Kim, Geoff Lennox, Bill Lewis, Dennis Liotta, Greg Melikian, Igho Ofotokun, Mirko Paiardini, Bali Pulendran, Arshed Quyyumi, Jyothi Rengarajan, Nabil Saba, Ray Schinazi, Anandi Sheth, Guido Silvestri, Anne Spaulding, Paul Spearman, Sam Speck, Rob Stephenson, Patrick Sullivan, Mehul Suthar, Roy Sutliff, Francois Villinger, Drenna Waldrop-Valverde, Ifor Williams, Mark Wilson, Frank Wong, Chinglai Yang, and Benjamin Youngblood
...and to 9 PIs whose NIH awards, even though they
do not count towards the CFAR's funded research base, collectively brought $13,049,042 in more NIH AIDS funding to Emory in FY2014:
Stewart Caughman, Jim Curran, Danielle Haley, Dean Jones, Meridith Mikulich, Emily
Russell, David Stephens, Joshua Strauss, and Aaron Vissman
In other news...
in NIH AIDS funding during FY2014
The Highest in Emory's History
Yay Team CFAR!!
(now all you have to do is keep it up for 2 more years!)
(FY2015 and FY2016)
... to Stuart Zola (April 23), Danny Branstetter (April 26), and Chinglai Yang (April 28)
True friends remember your birthday, but not your age – count us among your true friends
Our exhuberance above makes it sound like NIH is the only funder who supports Emory HIV/AIDS researchers. Au Contraire! Check this duo out...
Here's a problem ... the prevalence of HIV among inmates can be more than 3x higher than in the general public (yeah, gasp!) -- so how do you ensure that inmates don't take a dive off the continuum of care after they leave the joint? Enter the Professor and the Pop Star. Anne Spaulding has recently been awarded a second round of funding from the Elton John Foundation to link inmates with HIV to care before they leave the correctional system.
• Read the original article about it from her first round of funding
Inmates aren't the only ones who tend to wipe out when surfing the cascade of care ... It turns out that adolescents with HIV aren't any more compliant in following adult advice than your standard issue teenager is, which can be bad news for retention and treatment. Andres Camacho-Gonzalez has an app for that! Andres recently received funding from the Georgia Department of Health for HealthySteps: Improving HIV Treatment Compliance One Step at a Time, a mobile phone app that is specifically designed to increase linkage to care, retention in care, and medication adherence in HIV-infected adolescents
and young adults who have a history of poor treatment compliance.
HIV+ Study Subjects Wanted:
In the REPRIEVE (randomized trial to prevent vascular events in HIV) study, people with HIV between 40 - 75 yrs will be randomized to take the pill pitavastatin OR a placebo to see if pitavastatin can help prevent heart disease and death in people on HIV meds. The study lasts approximately 72 months (6 years) and you will not know if you are taking pitavastatin or placebo. The REPRIEVE trial is seeking to enroll 6500 people from several countries
• Read the study flyer
More HIV+ Study Subjects Wanted:
A5315 is a phase I/II, double-blinded, randomized, placebo-controlled, dose-escalation study to evaluate the safety and efficacy of a single dose administration of romidepsin (RMD). Three cohorts (1-3) of 15 subjects each will be sequentially enrolled into the study (depending on safety outcomes, which will determine whether to dose escalate or not). Toxicity related to the administration of RMD will be evaluated systematically.
• Read the study flyer
No HIV-related government news this week
New Biosketch Feedback Opportunity
Quoted from the Department of Medicine Researchers Listserv:
"Will you be submitting an NIH grant on or after May 25, 2015?"
"Is the new NIH biosketch format giving you anxiety?"
"Would you like suggestions and direct feedback on your newly-formatted biosketch from seasoned NIH reviewers?"
"If you answered "yes" to these questions, then you should consider submitting your newly-formatted biosketch to be reviewed at the upcoming Research Resources 101 session on May 21. We will select and showcase a few biosketches during that session to seek comments and suggestions for strategic improvement from our esteemed panel of NIH reviewers. If you would like to be considered for this unique opportunity to gain collective wisdom on your newly formatted biosketch, please submit a draft in the new format to Karen Summers (Karen.email@example.com) by Monday, May 7, 2015."